Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adenocarcinoma of the prostate
• •Relapsed disease after definitive local therapy, as documented only by a rise in prostate-specific antigen (PSA)
• •* Experienced PSA relapse after definitive local therapy
• •* Rising PSA (≥ 1.0 ng/mL after nadir \< 1.0 ng/mL)
• •* PSA increase of ≥ 0.3 ng/mL (increase occurred between 2 separate measurements taken ≥ 4 weeks apart)
• •* The first of these two PSA values must rise above a previously recorded post-therapy nadir value
• •Ineligible for curative therapy
• •No clinical evidence of local recurrence (i.e., palpable induration or mass in the prostatic fossa) other than PSA elevation
• •No evidence of palpable disease in the prostatic bed
• +48 more criteria